#COVID-19 vaccine

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

The nation’s top pandemic adviser joins a growing number of people catching the coronavirus during the omicron wave.

The good news is that only 4% of HIV-positive people experienced COVID breakthrough after vaccination.

Approximately 1 in 3 Americans 65 and older who completed their initial vaccination round still have not received a first booster shot.

People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.

National Comprehensive Cancer Network encourages second mRNA booster shot and offers COVID PrEP advice for people with cancer.

A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.

The United States might see one of the steepest increases in the country’s uninsured rate in years.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

Could the immune dysfunction that causes severe COVID in people with schizophrenia be what drives their psychotic symptoms?

The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.

The benefits of achieving herd immunity thresholds have been less successful with respiratory viruses that continually mutate.

Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.

A new report, “The State of Black America and COVID-19,” brings attention to health inequities, achievements and the work to be done.